Work

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

Year: 2017

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2017.07.011

Authors: Kenneth S. Thress, Vivien Jacobs, Helen K. Angell, James Chih-Hsin Yang, Lecia V. Sequist, Fiona Blackhall, Wu-Chou Su, Martin Schuler, Jürgen Wolf, Kathryn A. Gold, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne

Institutions: AstraZeneca (United States), AstraZeneca (United Kingdom), National Taiwan University Hospital, Massachusetts General Hospital, National Health Service, University of Manchester, The Christie NHS Foundation Trust, National Cheng Kung University Hospital, Essen University Hospital, University of Duisburg-Essen, University Hospital Cologne, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, Ariad Pharmaceuticals, Cancer Research UK, Astellas Pharma, Genentech, Merck Sharp and Dohme, Pharmacyclics

Awards: G8175362151, G892895007

OpenAlex ID: W2739122151

FWCI: 2.632

Cites: 15

Cited by: 24

Related to: 10